IL6ST (interleukin 6 signal transducer) is produced as a polypeptide with a molecular weight of 130kDa, and its glycosylated to a form of 150kDa weight. It functions a part of receptor signaling complexes for around eight cytokines.
Synonyms: Anti-CD130 antigen antibody produced in rabbit; Anti-CDw130 antibody produced in rabbit; Anti-IL-6R-beta antibody produced in rabbit; Anti-Interleukin-6 receptor subunit beta precursor antibody produced in rabbit; Anti-Interleukin-6 signal transducer antibody produced in rabbit; Anti-Membrane glycoprotein 130 antibody produced in rabbit; Anti-Oncostatin-M receptor alpha-subunit antibody produced in rabbit; Anti-gp130 antibody produced in rabbit
Storage: -20C
Application: Anti-IL6ST antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Deletion mutation in IL6ST (interleukin 6 signal transducer) is linked with inflammatory hepatocellular adenoma. Mutations in this gene lead to tumorigenesis, which might be a result of dysfunctional intracellular compartment signaling. Activation of this protein follows ligand-binding, and is succeeded by activation of multiple signaling pathways including, JAK/STAT (Janus kinase/signal transducer and activator of transcription), RAS (rat sarcoma)/RAF/MAPK (mitogen activated kinase), and PI3K (phosphoinositide 3-kinase)/AKT pathways. Circulating levels of soluble IL6ST is linked with the risk of myocardial infarction.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC